Showing results (91-100 of 258) with videos related to

Sort By:
Pageof 26
Critical Reviews in Oncology/Hematology|March 15, 2016
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trialsGiandomenico Roviello, Sandra Sigala, Romano Danesi, et al.
Expert Opinion on Biological Therapy|September 6, 2012
Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patientsMassimo Martino, Alberto Bottini, Giovanni Rosti, et al.
Clinical Breast Cancer|March 6, 2016
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast CancersGiandomenico Roviello, Manuela Milani, Angela Gobbi, et al.
Future Oncology (London, England)|October 7, 2017
Advances in systemic therapy for malignant mesothelioma: future perspectivesNavid Sobhani, Silvia Paola Corona, Deborah Bonazza, et al.
International Journal of Molecular Sciences|May 27, 2023
A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer DetectionMarina Bortul, Fabiola Giudici, Domenico Tierno, et al.
Medicine|October 28, 2016
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trialsGiandomenico Roviello, Maria Rosa Cappelletti, Laura Zanotti, et al.
World Neurosurgery|November 23, 2023
Intrasellar Dermoid Cyst: Case Report of a Rare Lesion and Systematic Literature Review Comparing Intrasellar, Suprasellar, and Parasellar LocationsCarmine Antonio Donofrio, Giacomo Bertazzoni, Lucia Riccio, et al.
Critical Reviews in Oncology/Hematology|March 23, 2017
CDK4/6 inhibitors in HER2-positive breast cancerSilvia Paola Corona, Andrea Ravelli, Daniele Cretella, et al.
Seminars in Oncology|September 6, 2023
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?Antonella Ferro, Daniele Generali, Orazio Caffo, et al.
Scientific Reports|September 12, 2019
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cellsDaniele Cretella, Claudia Fumarola, Mara Bonelli, et al.
Pageof 26